A. Y. Kornilova, M. S. Wolfe (2001). Secretase inhibitors for Alzheimer’s disease. Annu. Rep.
Med. Chem. 38: 41.
J. P. Taylor, J. Hardy, K. Fischbeck (2002). Toxic proteins in neurodegenerative disease. Science
296 : 1991–1995.
P. A. Temussi, L. Masino, A. Pastore (2003). From Alzheimer to Huntington: Why is a structural
understanding so difficult? EMBO J. 22: 355–361.
D. Selkoe (1999). Translating cell biology into therapeutic advances in Alzheimer’s disease.
Nature 399(Suppl.): A23–A31.
D. Selkoe (2003). Folding proteins in fatal ways. Nature 426: 900–905.
Lipids as Drug Design Targets
P. G. Adaikan, S. R. Kottegoda (1985). Prostacyclin analogs. Drugs Future 10: 765–774.
M. R. Bell, F. H. Barzold, R. C. Winneker (1986). Chemical control of fertility. Annu.Rep. Med.
Chem. 21: 169–177.
K. Brune, K. D. Rainsford (1980). New trends in the understanding and development of anti-
inflammatory drugs. Trends Pharmacol. Sci. 1: 95–97.
D. A. Clark, A. Marfat (1982). Structure elucidation and the total synthesis of leukotrienes. Annu.
Rep. Med. Chem. 17: 291–300.
R. A. Coleman, P. P. A. Humphrey, I. Kennedy, P. Lumley (1984). Prostanoid receptors—the
development of a working classification. Trends Pharmacol. Sci. 5: 303–306.
C. A. Dinarello (1984). Interleukin-1: an important mediator of inflammation. Trends Pharmacol.
Sci. 5: 420–422.
C. Funk (2001). Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294:
1871–1875.
J. G. Gleason, C. D. Perchonock, T. J. Torphy (1986). Pulmonary and antiallergy agents. Annu.
Rep. Med. Chem. 21: 73–83.
R. R. Gorman (1978). Prostaglandins, thromboxanes and prostacyclin. Int. Rev. Biochem. 20:
91–107.
P. Gund, J. D. Andose, J. B. Rhodes, G. M. Smith (1980). Three-dimensional molecular model-
ing and drug design. Science 208: 1625–1731.
F. D. Hart, E. C. Huskinson (1984), Non-steroidal antiinflammatory drugs: current status and
rational therapeutic use. Drugs 27: 232–255.
S. Kaivola, J. Paratainen, T. Osterman, H. Tiomonen (1983). Cephalagia 3: 31–36; as quoted in
Trends Pharmacol. Sci. 6: 435 (1995).
W. Kreutner, M. I. Siegel (1984). Biology of leukotrienes. Annu. Rep. Med. Chem. 19: 241–251.
M. Kucher, V. Rejholec (1986). Antithrombotic agents. Drugs Future 11: 687–701.
W. E. M. Lands (1985). Mechanism of action of antiinflammatory drugs. Adv. Drug Res. 14:
147–164.
A. Lupulescu (1996). Prostaglandins, their inhibitors and cancer. Prostaglandins, Leukotrienes
and Essential Fatty Acids 54: 83–94.
R. Nickander, F. G. McMahon, A. S. Ridollo (1979). Non-steroidal anti-inflammatory agents:
Annu. Rev. Pharmacol.Toxicol. 19: 649–690.
K. C. Nicolaou, J. B. Smith (1979). Prostacyclin, thromboxane and the arachidonic acid cascade:
Annu. Rep. Med. Chem. 14 : 178–187.
J. E. Pike, D. R. Morton, Jr (Eds.) (1985). Advances in Prostaglandin, Thromboxane, and
Leukotriene Research, vol. 14. New York: Raven Press.
K. D. Rainsford (1985). Anti-inflammatory and Anti-rheumatic Drugs, 3 vols. Boca Raton: CRC
Press.
ENDOGENOUS MACROMOLECULES 541